Hetero is one of India’s leading generic pharmaceutical companies and is the world’s largest global producer of anti-retroviral drugs for the treatment of HIV/AIDS. Founded in 1993 by Dr. B.P.S Reddy, Hetero has grown rapidly in over two decades, based on a tradition of excellence, a strong-minded focus on cost-effective integration and with a deep sense of commitment towards making life-saving medicines accessible to patients worldwide.
Hetero, a research-driven pharmaceutical company, is committed to the development, manufacturing and marketing of active pharmaceutical ingredients (APIs), intermediates and finished dosages. Today, Hetero is recognized as a world leader in process chemistry, API manufacturing, formulation development, manufacturing and commercialization.
Hetero has around 18 state-of-the-art manufacturing facilities, which are cGMP compliant and have been approved by various Ministries of Health and regulatory authorities like US FDA, WHO, MCC - South Africa, MHRA-UK, TGA – Australia, PMDA – Japan, KFDA (Korea) among others. The company has a rich manufacturing product portfolio of over 200 products across a wide range of therapeutic categories. Hetero has a strong global presence in over 120 countries and has been offering API’s and generic formulations to partners across the globe.
While Hetero is committed towards leveraging its expertise in the area of pharmaceuticals, it is also focusing on Biotechnology and also on developing New Chemical Entities (NCEs) in select therapeutic areas.
Hetero, a privately-owned company, is recognized as one of the top 10 companies in the Indian pharmaceutical industry with an annual turnover of US$ 1.2 billion. With a dedication and support of its 15,000 employees, Hetero continues its commitment to manufacture high-quality drugs and save millions of lives across the world.
Dr. B.P.S Reddy
Chairman & Managing Director
Dr. B.P.S Reddy, CMD of Hetero Group founded the company in 1993 through an initial purchase of an API manufacturing facility. Over the past 20 years, he has nurtured this company to be the largest privately-held company in India and the world leader in the production of anti-retroviral drugs. Under the leadership of Dr B.P.S Reddy, Hetero played a significant role during the HIV/AIDS crisis by developing the first affordable APIs for anti-retroviral drugs. The company today is regarded for its pioneering efforts for manufacturing a wide range of anti-retroviral drugs at an affordable cost.
Before Hetero had its humble beginnings, Dr. BPS Reddy was associated with Dr Reddy's Labs as the Head of Research and Development, where he successfully led the teams during their first ever FDA audit.
At Hetero, Dr. B.P.S Reddy leveraged his expertise in synthetic chemistry and leadership roles in Research and Development to create one of the best generic API companies in the world. He is also credited for his vision on ARVs where Hetero is a significant challenger today.
We are privileged to have Dr. B.P.S Reddy as our founder and Chairman. He has enabled Hetero to become a global player with unparalleled strengths in research, manufacturing, and marketing. His vision for the advancement of healthcare has contributed to improve lives for millions of people.